Pfizer (PFE.US) has applied for clinical trials of its innovative cancer drug in China for the first time, targeting KRAS mutation tumors.
On December 5, the official website of the China National Medical Products Administration's Center for Drug Evaluation (CDE) announced that Pfizer's (PFE.US) class 1 new drug PF-07934040 tablet clinical trial application has been accepted.
Pfizer Options Spot-On: On December 4th, 124.98K Contracts Were Traded, With 3.39 Million Open Interest
10 Health Care Stocks Whale Activity In Today's Session
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Pfizer Options Spot-On: On December 3rd, 127.27K Contracts Were Traded, With 3.33 Million Open Interest
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
蛇蛇 : Next January, take Route 35.
Amusement World : Was demolished lol
J L 7 2 : He will definitely lose money today
